GSK Puts Faith In Next Gen Respiratory, Real World Studies
Company Seeks Edge Over Rival AZ
A pioneer in the field, can GSK’s investment in real world studies pay off?
You may also be interested in...
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.